(379) Actively targeting colorectal cancer using nanoparticles co-loaded with small molecule inhibitors

The combination of BRAF V600E inhibitors (e.g., encorafenib, dabrafenib) and MEK inhibitors (e.g., trametinib, binimetinib) offers second-line therapy for metastatic colorectal cancer (CRC) with BRAF V600E mutations, effectively blocking the MAPK/ERK pathway. However, poor solubility, bioavailability, nonspecific distribution, and resistance limit its potential as a primary therapy. To address this, we developed cRGD-functionalized nanoparticles co-loaded with encorafenib and trametinib (cRGD-ET-NPs), enhancing efficacy at maximum tolerated doses in a murine xenograft CRC model.